{
  "id": "fda_guidance_chunk_0560",
  "title": "Introduction - Part 560",
  "text": "all clinical investigations of products that are subject to section 505 of the FD&C Act or to section 351 of the PHS Act (see 21 CFR 312.2(a)). The intended use of a product plays a central role in how it is regulated. For example, products that contain live microorganisms may be regulated as dietary supplements, conventional foods, or drugs under the FD&C Act, depending on the product’s intended use and other factors relevant to the statutory definition of the product category.5 The intended use of a product in a clinical investigation determines whether IND requirements for clinical investigation of the product are applicable.6 Note that under section 201(ff)(3)(B)(ii) of the FD&C Act (21 U.S.C. 321(ff)(3)(B)(ii)), if an LBP that meets the other parts of the dietary supplement definition in section 201(ff) is authorized for investigation under an IND, and was marketed as a dietary supplement or conventional food before the IND was authorized, it may continue to be marketed as a dietary supplement despite the existence of the IND.7 Under section 301(ll) of the FD&C Act (21 U.S.C. 331(ll)), if substantial clinical investigations of an LBP as a drug or biologic were instituted before the LBP was marketed in food, a food 5 See “Draft Guidance for Industry: Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration” dated December 2006 at page 4, issued for public comment and available at http://www.fda.gov/RegulatoryInformation/Guidances/ucm144657.htm. 6 See also “Guidance for Clinical Investigators, Sponsors, and IRBs: Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND” dated September 2013, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM229175.pdf. A stay is in effect for parts of this guidance document. See “Investigational New Drug Applications (INDs) – Determining Whether Human Research Studies Can Be Conducted Without an IND; Guidance for Clinical Investigators, Sponsors, and IRBs; Partial Stay and Republication of Guidance” (80 FR 66907, October 30, 2015). 7 If an LBP was not marketed as a dietary supplement or conventional food before the IND was authorized, the LBP may only be marketed as a dietary supplement if one or more of the following is true: (1) substantial clinical investigations of the LBP have not been instituted; (2) the existence of substantial clinical investigations of the LBP (if such clinical investigations were instituted) has not",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 751296,
  "end_pos": 752832,
  "tokens": 512,
  "tags": [
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "recommendation",
  "created_at": "2025-10-23T02:25:44.720Z"
}